paroxetine has been researched along with methylphenidate in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alexoff, DA; Chen, R; Dewey, SL; Ding, YS; Fowler, JS; Gatley, SJ; Pan, D | 1 |
| Cole, JO; Diamond, L; Pillay, SS; Stoll, AL; Workum, SB | 1 |
| Hause, S; Huether, G; Moll, GH; Rothenberger, A; Rüther, E | 1 |
| Hotopf, M; Minton, O; Richardson, A; Sharpe, M; Stone, P | 1 |
| Bekker, EM; Buitelaar, JK; Kenemans, JL; Kooij, JJ; Overtoom, CC; van der Molen, MW; Verbaten, MN | 1 |
| Becker, A; Bock, N; Manzke, T; Roessner, V; Rothenberger, A | 1 |
| Palshof, T; Pedersen, L | 1 |
| Jung, YK; Park, YM | 1 |
| Dimpfel, W | 1 |
| Adak, I; Akaltun, I; Coskun, M | 1 |
| Alfano, CM; Heckler, C; Kleckner, AS; Kleckner, IR; Leach, CR; Miller, SM; Mohr, D; Mustian, KM; Palesh, OG; Peppone, LJ; Piper, BF; Scarpato, J; Smith, T; Sprod, LK | 1 |
| Boldt, G; Bruera, E; Chiu, L; Chow, R; Lock, M; Prsic, E; Sanatani, M | 1 |
5 review(s) available for paroxetine and methylphenidate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.
Topics: Anemia; Antidepressive Agents, Second-Generation; Antineoplastic Agents; Central Nervous System Stimulants; Darbepoetin alfa; Dopamine Uptake Inhibitors; Erythropoietin; Fatigue; Hematinics; Humans; Methylphenidate; Neoplasms; Odds Ratio; Paroxetine; Progestins; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
[Pharmaceutical treatment of cancer-associated fatigue--a survey of a Cochrane review].
Topics: Antidepressive Agents, Second-Generation; Central Nervous System Stimulants; Erythropoietin; Evidence-Based Medicine; Fatigue; Hematinics; Humans; Methylphenidate; Neoplasms; Paroxetine; Progestins; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2009 |
Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis.
Topics: Benzhydryl Compounds; Central Nervous System Stimulants; Cognitive Behavioral Therapy; Dexmethylphenidate Hydrochloride; Dextroamphetamine; Exercise Therapy; Fatigue; Glucocorticoids; Humans; Methylphenidate; Methylprednisolone; Modafinil; Neoplasms; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Wakefulness-Promoting Agents | 2017 |
Cancer-related fatigue-pharmacological interventions: systematic review and network meta-analysis.
Topics: Central Nervous System Stimulants; Fatigue; Humans; Methylphenidate; Modafinil; Neoplasms; Network Meta-Analysis; Paroxetine | 2023 |
2 trial(s) available for paroxetine and methylphenidate
| Article | Year |
|---|---|
Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series.
Topics: Adult; Aged; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Methylphenidate; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1996 |
Methylphenidate restores link between stop-signal sensory impact and successful stopping in adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Cerebral Cortex; Double-Blind Method; Female; Humans; Inhibition, Psychological; Male; Methylphenidate; Paroxetine; Placebos; Reaction Time; Selective Serotonin Reuptake Inhibitors | 2009 |
15 other study(ies) available for paroxetine and methylphenidate
| Article | Year |
|---|---|
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Binding of bromine-substituted analogs of methylphenidate to monoamine transporters.
Topics: Animals; Binding, Competitive; Bromine; Carrier Proteins; Chromatography, High Pressure Liquid; Cocaine; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; In Vitro Techniques; Magnetic Resonance Spectroscopy; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methylphenidate; Mice; Microdialysis; Motor Activity; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Tomography, Emission-Computed, Single-Photon | 1994 |
Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters.
Topics: Animals; Brain Chemistry; Carrier Proteins; Central Nervous System Stimulants; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; Kinetics; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Membranes; Mesencephalon; Methylphenidate; Neostriatum; Nerve Tissue Proteins; Paroxetine; Piperazines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2001 |
Development of 5-HT transporter density and long-term effects of methylphenidate in an animal model of ADHD.
Topics: Age Factors; Animals; Attention Deficit Disorder with Hyperactivity; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Methylphenidate; Paroxetine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Drug; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 2009 |
Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression.
Topics: Adolescent; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Male; Methylphenidate; Paroxetine; Serotonin Syndrome; Treatment Outcome | 2010 |
Pharmacological classification of herbal extracts by means of comparison to spectral EEG signatures induced by synthetic drugs in the freely moving rat.
Topics: Animals; Brain; Caffeine; Electroencephalography; Magnoliopsida; Methylphenidate; Paroxetine; Phenytoin; Plant Extracts; Rats; Tramadol | 2013 |
Bilateral gynecomastia in a preadolescent boy while under treatment with methylphenidate and paroxetine.
Topics: Child; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Gynecomastia; Humans; Male; Methylphenidate; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2014 |